US Stocks | Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Kailera sold roughly 39 million shares at $16 and opened at $26, a >60% surge on its Nasdaq debut.
- Metsera raised $275 million in its Jan 2025 IPO at a $1.8 billion valuation and was later bought by Pfizer for up to $10 billion.
- GLP‑1 drug market is projected to reach $150 bn annually by the end of the decade, fueling intense investor interest.
- Lukas Muehlbauer (IPOX Research) notes obesity remains a rare biotech area with clear investor appetite, and near‑term trading will be shaped by GLP‑1 fundamentals.
- Kailera’s pipeline includes KAI‑9531 (global Phase 3 GLP‑1/GIP injectable) and KAI‑7535 (once‑daily oral GLP‑1 agonist), with readouts not expected until 2028.
Why it matters: Kailera’s 60% pop gives investors direct exposure to the $150bn GLP‑1 obesity market by 2030.
